@ciencia.60's Ozempic claims need some corrections

What did @ciencia.60 actually say?

Honestly? It's hard to tell. The transcript from this 644K-view TikTok is largely incoherent, reading more like a garbled auto-transcription than a coherent science explainer. Phrases like "send the first lessons and rewards in the event" and "you can't get cut by that" don't correspond to any recognizable claim about semaglutide or GLP-1 biology. The caption promises to explain how Ozempic works in your body, but the transcript doesn't deliver that content in any legible form.

That said, the video's framing, its hashtags, caption, and apparent premise, suggests it was intended to explain semaglutide's mechanism of action for weight loss. We're going to fact-check that premise directly, because 644,000 people watched this and presumably got some version of that explanation. The claims we assess below are drawn from the stated intent of the video, not fabricated content.

Does the science back up how Ozempic actually works?

Yes, the basic science here is well-established, even if this video couldn't articulate it clearly. Semaglutide is a GLP-1 receptor agonist. GLP-1, glucagon-like peptide-1, is a hormone your gut releases after eating. Semaglutide mimics it at a much longer duration than your body's natural version.

Here's what that actually does. It stimulates insulin release from the pancreas when blood sugar is elevated. It suppresses glucagon, which would otherwise tell your liver to dump more glucose into your bloodstream. It slows gastric emptying, meaning food moves through your stomach more slowly, which extends satiety. And critically, it acts on GLP-1 receptors in the hypothalamus, reducing appetite signaling directly in the brain. Wilding et al. (2021, NEJM) showed semaglutide at 2.4mg weekly produced a mean body weight reduction of 14.9% over 68 weeks in people without diabetes. That's not a placebo effect. That's a drug hitting a well-understood biological target.

What did they get wrong, or right?

We can't fairly say the creator got specific facts wrong when the transcript is this garbled. What we can say is that the framing of Ozempic as primarily "el fármaco más buscado del mundo para adelgazar" (the most searched weight loss drug in the world) is accurate as a cultural observation, but it flattens important clinical context.

Semaglutide was approved first for type 2 diabetes management, not weight loss. Ozempic's FDA indication remains type 2 diabetes. Wegovy, the higher-dose formulation, carries the obesity indication. Conflating the two brand names is a common and consequential error that circulates widely on social media. Davies et al. (2021, Diabetes Care) confirmed semaglutide's glycemic benefits independently of weight loss, which matters for how clinicians think about prescribing it. If this video treated Ozempic as simply a diet drug, it missed half the pharmacology.

What should you actually know?

A few things that most Ozempic TikToks won't tell you. First, the weight loss effects are largely dependent on continued use. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that participants regained about two-thirds of lost weight within a year of stopping semaglutide. This is not a one-time fix.

Second, GLP-1 receptors are distributed throughout the body, including the heart, kidneys, and brain. The cardiovascular benefits seen in the SUSTAIN-6 trial (Marso et al., 2016, NEJM) were not trivial. For people with type 2 diabetes at high cardiovascular risk, semaglutide reduced major adverse cardiovascular events. That's a different conversation than weight loss alone.

Third, side effects are real. Nausea, vomiting, and gastrointestinal distress are the most common, particularly during dose escalation. Rare but serious risks include pancreatitis and, in rodent studies (not conclusively in humans), thyroid C-cell tumors. Anyone considering semaglutide should have this conversation with a licensed clinician, not base their decision on TikTok content, however well-intentioned.